Attenuated live vaccines are expected to emerge as the dominant vaccine type segment over the forecast period
Attenuated live vaccines segment is the largest segment among the vaccine type segments, which was estimated to create close to US$ 90 Mn, or more than 30% share of the total market in 2016. By the end of 2026, attenuated live vaccines segment is projected to reach more than US$ 150 Mn, expanding at a CAGR of 5.8% over the forecast period. Greater adoption of live attenuated vaccines is expected to contribute to the attractive absolute $ opportunity of the segment. Attenuated live vaccines segment is expected to be the most lucrative in the MEA veterinary vaccines market with a market attractiveness index of 2.0.
Rising incidence of food borne and zoonotic diseases in MEA countries likely to fuel the demand for attenuated live vaccines